Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Sell
25
HOTH Quote, Financials, Valuation and Earnings
Last price:
$1.00
Seasonality move
:
-5.37%
Day range:
$1.00 - $1.04
52-week range:
$0.66 - $3.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.90x
Volume:
220.7K
Avg. volume:
200.9K
1-year change:
32.89%
Market cap:
$15.7M
Revenue:
--
EPS (TTM):
-$1.06
Analysts' Opinion
-
Consensus RatingHoth Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.00, Hoth Therapeutics, Inc. has an estimated upside of 395.05% from its current price of $1.01.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $1.01.
Fair Value
-
According to the consensus of 1 analyst, Hoth Therapeutics, Inc. has 395.05% upside to fair value with a price target of $5.00 per share.
HOTH vs. S&P 500
-
Over the past 5 trading days, Hoth Therapeutics, Inc. has underperformed the S&P 500 by -6.91% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Hoth Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Hoth Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Hoth Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Hoth Therapeutics, Inc. has grown year-over-year earnings for 15 quarters straight. In the most recent quarter Hoth Therapeutics, Inc. reported earnings per share of -$0.30.
Enterprise value:
7.8M
EV / Invested capital:
0.95x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.81x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$4.4K
Return On Assets:
-127.43%
Net Income Margin (TTM):
--
Return On Equity:
-138.58%
Return On Invested Capital:
-138.18%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -$4.4K | -- | -- | |
| Operating Income | -$9.4M | -$7.8M | -$12.1M | -$2.2M | -$4.1M | |
| EBITDA | -$9.4M | -$7.8M | -$12.1M | -$2.2M | -$4.1M | |
| Diluted EPS | -$4.72 | -$1.45 | -$1.06 | -$0.32 | -$0.30 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $14.8M | $9.5M | $12.1M | $8.2M | $8.9M | |
| Total Assets | $15.2M | $9.9M | $12.1M | $8.3M | $9.2M | |
| Current Liabilities | $1.6M | $1M | $1.6M | $810.3K | $1M | |
| Total Liabilities | $1.8M | $1.3M | $1.6M | $813K | $1M | |
| Total Equity | $13.3M | $8.6M | $10.5M | $7.5M | $8.2M | |
| Total Debt | -- | -- | -- | $2.7K | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7.9M | -$8M | -$9.7M | -$1.6M | -$2.5M | |
| Cash From Investing | -$7.5K | -- | -$300K | -- | -$300K | |
| Cash From Financing | $11.4M | $3.7M | $9.8M | -- | $1.6M | |
| Free Cash Flow | -$7.9M | -$8M | -$9.7M | -$1.6M | -$2.5M | |
HOTH
Sector
Market Cap
$15.7M
$28.2M
Price % of 52-Week High
26.58%
50.25%
Dividend Yield
0%
0%
Shareholder Yield
-41.59%
-1.54%
1-Year Price Total Return
32.9%
-18.1%
Beta (5-Year)
0.645
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.07
200-day SMA
Sell
Level
$1.22
Bollinger Bands (100)
Sell
Level
1.13 - 1.59
Chaikin Money Flow
Sell
Level
-260.7M
20-day SMA
Sell
Level
$1.14
Relative Strength Index (RSI14)
Sell
Level
34.10
ADX Line
Sell
Level
18.79
Williams %R
Buy
Level
-96
50-day SMA
Sell
Level
$1.23
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
832.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-9.0912)
Sell
CA Score
(Annual)
Level (-2.6889)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (19.1501)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, HOTH has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The HOTH average analyst price target in the past 3 months is $5.00.
-
Where Will Hoth Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Hoth Therapeutics, Inc. share price will rise to $5.00 per share over the next 12 months.
-
What Do Analysts Say About Hoth Therapeutics, Inc.?
Analysts are divided on their view about Hoth Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Hoth Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Hoth Therapeutics, Inc.'s Price Target?
The price target for Hoth Therapeutics, Inc. over the next 1-year time period is forecast to be $5.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is HOTH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Hoth Therapeutics, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of HOTH?
You can purchase shares of Hoth Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Hoth Therapeutics, Inc. shares.
-
What Is The Hoth Therapeutics, Inc. Share Price Today?
Hoth Therapeutics, Inc. was last trading at $1.00 per share. This represents the most recent stock quote for Hoth Therapeutics, Inc.. Yesterday, Hoth Therapeutics, Inc. closed at $1.01 per share.
-
How To Buy Hoth Therapeutics, Inc. Stock Online?
In order to purchase Hoth Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get HOTH Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
HOTH
Sector
P/E ratio
--
23.92x
PEG ratio
--
-0.01x
P/B ratio
1.90x
1.83x
Price / LTM sales
--
1.61x
Growth Metrics
HOTH
Sector
Revenue growth
--
4.6%
Earnings growth
7.77%
10.88%
Revenue (5-year growth)
--
6.46%
Earnings forecast
-$0.27
-$0.21
Profitability
HOTH
Sector
Profitability FY 2024
--
$3.5M
Return on invested capital
-138.18%
-31.84%
Return on assets
-127.43%
-27.96%
Return on equity
-138.58%
-37.63%
Earnings Date
Last Earnings Date
Dec
30
Next Earnings Date
Dec
30
Estimated Next Earnings Date
Mar
31
Balance Sheet
HOTH
Sector
Total cash
$7.8M
$26.3M
Short term investments
--
$25.7M
Total assets
$7.7M
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 29
Galecto, Inc. [GLTO] is down 12.13% over the past day.
Sell
20
SMX alert for Dec 29
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Sell
11
CDNAF alert for Dec 29
Canadian Tire Corp. Ltd. [CDNAF] is up 11.94% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
